Product Reports Resources Pricing Login Book a demo

Gelmetix

Biotech & Life Sciences · London, United Kingdom · Founded 2012

Injectable polymer gel for non-surgical chronic pain treatment MoreLess

Gelmetix is a UK-based medical device company developing non-surgical alternatives for chronic pain associated with osteoarthritis and degenerative disc disease. Spun out of the University of Manchester in 2012, the company was founded based on over two decades of research by Professor Tony Freemont and Professor Brian Saunders. Their work led to a patented polymer gel technology that forms injectable, durable, load-bearing gels designed to mimic the body's natural joint lubricants.

The company's lead product, DXM, is a minimally invasive, injectable hydrogel for treating chronic lower back pain caused by degenerative disc disease. Delivered in a single injection, DXM works by supplementing and rehydrating the nucleus pulposus—the core of the intervertebral disc—to restore its function, relieve pain, and potentially slow the degenerative process. This approach is positioned as a treatment option between conservative pain management, like opiate-based medication, and major surgery. The company has received approval from the French regulator (ANSM) to commence first-in-human trials.

Gelmetix's business model focuses on developing and commercializing its portfolio of biomaterial medical devices. The company has secured significant funding through multiple rounds, including a £1.2 million Series B in 2018 and a £5 million Series C in 2021, to advance its clinical trials and prepare for commercial launch. Beyond back pain, Gelmetix is developing its technology platform for other applications, including treating osteoarthritis in small joints (SXM product) and as a carrier for regenerative agents like stem cells.

Keywords: chronic lower back pain, injectable hydrogel, degenerative disc disease, nucleus pulposus augmentation, medical device, non-surgical treatment, biomaterials, osteoarthritis, polymer technology, spine degeneration, minimally invasive procedure, orthopaedics, pain management, disc rehydration, intervertebral disc, clinical trials, medtech, load-bearing gel, joint lubrication, cartilage repair

Talent graph

Gelmetix's talent

Book a demo to see the people
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

6 investors on Gelmetix's cap table

Sourced from Dealroom's funding and investor records.

Seed 4 investors entered at this stage
The North West Fund
Syndicate Room
Seneca Partners
Jonathan Milner
Series A 2 investors entered at this stage
The University of Manchester
Wealth Club

Global footprint

Where Gelmetix has talent and traffic

Workforce by country
3 countries with
team presence
🇬🇧 United Kingdom75%
🇨🇭 Switzerland12.5%
🇺🇸 United States12.5%
3 countries shown

Market sentiment

What the market is saying about Gelmetix

An AI-synthesized read of the highest-engagement posts about Gelmetix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Gelmetix on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.